"Sildenafil Citrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.
| Descriptor ID |
D000068677
|
| MeSH Number(s) |
D02.065.884.675 D02.886.590.700.675 D03.383.606.854 D03.633.100.759.824
|
| Concept/Terms |
Sildenafil Citrate- Sildenafil Citrate
- Citrate, Sildenafil
- 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
UK 92480-10- UK 92480-10
- UK 92480 10
- UK 9248010
- UK-92,480-10
- UK 92,480 10
|
Below are MeSH descriptors whose meaning is more general than "Sildenafil Citrate".
Below are MeSH descriptors whose meaning is more specific than "Sildenafil Citrate".
This graph shows the total number of publications written about "Sildenafil Citrate" by people in this website by year, and whether "Sildenafil Citrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 5 | 5 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sildenafil Citrate" by people in Profiles.
-
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial. J Pediatr. 2026 Aug; 295:115147.
-
Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis. Cardiol Young. 2023 Nov; 33(11):2297-2311.
-
Risk Stratification by Percent Liver Herniation in Congenital Diaphragmatic Hernia. J Surg Res. 2023 02; 282:168-173.
-
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children. Pediatr Pulmonol. 2021 03; 56(3):593-613.
-
Evaluation of Sildenafil and Tadalafil for Reversing Constriction of Fetal Arteries in a Human Placenta Perfusion Model. Hypertension. 2018 07; 72(1):167-176.
-
Prenatal intervention for the management of congenital diaphragmatic hernia. Pediatr Surg Int. 2018 Jun; 34(6):579-587.
-
VISION LOSS IN A PATIENT WITH PRIMARY PULMONARY HYPERTENSION AND LONG-TERM USE OF SILDENAFIL. Retin Cases Brief Rep. 2017 Fall; 11(4):325-328.
-
AMPK and Endothelial Nitric Oxide Synthase Signaling Regulates K-Ras Plasma Membrane Interactions via Cyclic GMP-Dependent Protein Kinase 2. Mol Cell Biol. 2016 12 15; 36(24):3086-3099.
-
Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther. 2016; 10:3661-3672.
-
Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension. Pediatr Pulmonol. 2017 02; 52(2):232-237.